{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:49:48Z","timestamp":1792496988492,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40262-023-01245-3","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T18:02:30Z","timestamp":1682704950000},"page":"673-692","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical and Pre-Clinical Pharmacokinetics and Pharmacodynamics of Bentracimab"],"prefix":"10.1007","volume":"62","author":[{"given":"Luis","family":"Ortega-Paz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Franchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Rollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Charles V.","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"issue":"17","key":"1245_CR1","doi-asserted-by":"publisher","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","volume":"17","author":"DJ Angiolillo","year":"2022","unstructured":"Angiolillo DJ, Galli M, Collet JP, Kastrati A, O\u2019Donoghue ML. Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention. 2022;17(17):e1371\u201396.","journal-title":"EuroIntervention"},{"issue":"2","key":"1245_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41569-021-00598-1","volume":"19","author":"D Capodanno","year":"2022","unstructured":"Capodanno D, Bhatt DL, Gibson CM, James S, Kimura T, Mehran R, et al. Bleeding avoidance strategies in percutaneous coronary intervention. Nat Rev Cardiol. 2022;19(2):117\u201332.","journal-title":"Nat Rev Cardiol"},{"issue":"25","key":"1245_CR3","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1161\/CIRCULATIONAHA.113.003675","volume":"128","author":"D Capodanno","year":"2013","unstructured":"Capodanno D, Angiolillo DJ. Management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery. Circulation. 2013;128(25):2785\u201398.","journal-title":"Circulation"},{"issue":"8","key":"1245_CR4","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1055\/s-0042-1753485","volume":"48","author":"B Salter","year":"2022","unstructured":"Salter B, Crowther M. A historical perspective on the reversal of anticoagulants. Semin Thromb Hemost. 2022;48(8):955\u201370.","journal-title":"Semin Thromb Hemost"},{"key":"1245_CR5","doi-asserted-by":"crossref","unstructured":"Capodanno D, Milluzzo RP, Angiolillo DJ. Intravenous antiplatelet therapies (glycoprotein IIb\/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use. Ther Adv Cardiovasc Dis. 2019;13:1753944719893274.","DOI":"10.1177\/1753944719893274"},{"issue":"1","key":"1245_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jcin.2022.10.034","volume":"16","author":"F Franchi","year":"2023","unstructured":"Franchi F, Ortega-Paz L, Rollini F, Galli M, Been L, Ghanem G, et al. Cangrelor in patients with coronary artery disease pretreated with ticagrelor: the Switching Antiplatelet (SWAP)-5 Study. JACC Cardiovasc Interv. 2023;16(1):36\u201346.","journal-title":"JACC Cardiovasc Interv"},{"issue":"10","key":"1245_CR7","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1586\/14779072.2013.837701","volume":"11","author":"F Franchi","year":"2013","unstructured":"Franchi F, Rollini F, Muniz-Lozano A, Cho JR, Angiolillo DJ. Cangrelor: a review on pharmacology and clinical trial development. Expert Rev Cardiovasc Ther. 2013;11(10):1279\u201391.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"2","key":"1245_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1001\/jamacardio.2016.4556","volume":"2","author":"M Vaduganathan","year":"2017","unstructured":"Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, Gibson CM, et al. Evaluation of ischemic and bleeding risks associated with 2 parenteral antiplatelet strategies comparing cangrelor with glycoprotein IIb\/IIIa inhibitors: an exploratory analysis from the CHAMPION trials. JAMA Cardiol. 2017;2(2):127\u201335.","journal-title":"JAMA Cardiol."},{"issue":"2","key":"1245_CR9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jacc.2016.10.055","volume":"69","author":"M Vaduganathan","year":"2017","unstructured":"Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, Gibson CM, et al. Cangrelor with and without glycoprotein IIb\/IIIa inhibitors in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2017;69(2):176\u201385.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"1245_CR10","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","volume":"368","author":"DL Bhatt","year":"2013","unstructured":"Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14):1303\u201313.","journal-title":"N Engl J Med"},{"issue":"14","key":"1245_CR11","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.118.038317","volume":"139","author":"F Franchi","year":"2019","unstructured":"Franchi F, Rollini F, Rivas A, Wali M, Briceno M, Agarwal M, et al. Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation. 2019;139(14):1661\u201370.","journal-title":"Circulation"},{"issue":"24","key":"1245_CR12","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMra071014","volume":"357","author":"G Davi","year":"2007","unstructured":"Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357(24):2482\u201394.","journal-title":"N Engl J Med"},{"key":"1245_CR13","unstructured":"US FDA. Prasugrel FDA label. 2009. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022307s002lbl.pdf. Accessed 28 Dec 2022."},{"issue":"12","key":"1245_CR14","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1111\/jth.13511","volume":"14","author":"R Teng","year":"2016","unstructured":"Teng R, Carlson GF, Nylander S, Andersson TL. Effects of autologous platelet transfusion on platelet inhibition in ticagrelor-treated and clopidogrel-treated subjects. J Thromb Haemost. 2016;14(12):2342\u201352.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"1245_CR15","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/ccd.23297","volume":"79","author":"S Sharma","year":"2012","unstructured":"Sharma S, Bhambi B. Use of platelet transfusion to facilitate surgery in patients on clopidogrel and aspirin therapy after drug-eluting stent percutaneous coronary intervention. Catheter Cardiovasc Interv. 2012;79(3):498 (author reply 9\u2013500).","journal-title":"Catheter Cardiovasc Interv"},{"issue":"16","key":"1245_CR16","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.jcin.2018.04.022","volume":"11","author":"S Ariotti","year":"2018","unstructured":"Ariotti S, Ortega-Paz L, van Leeuwen M, Brugaletta S, Leonardi S, Akkerhuis KM, et al. Effects of ticagrelor, prasugrel, or clopidogrel on endothelial function and other vascular biomarkers: a randomized crossover study. JACC Cardiovasc Interv. 2018;11(16):1576\u201386.","journal-title":"JACC Cardiovasc Interv"},{"issue":"11","key":"1245_CR17","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.jacc.2018.01.027","volume":"71","author":"S Ariotti","year":"2018","unstructured":"Ariotti S, van Leeuwen M, Brugaletta S, Leonardi S, Akkerhuis KM, Rimoldi SF, et al. Effects of ticagrelor, prasugrel, or clopidogrel at steady state on endothelial function. J Am Coll Cardiol. 2018;71(11):1289\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1245_CR18","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1124\/dmd.110.032250","volume":"38","author":"R Teng","year":"2010","unstructured":"Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010;38(9):1514\u201321.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"1245_CR19","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1124\/dmd.110.037143","volume":"39","author":"D Zhou","year":"2011","unstructured":"Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos. 2011;39(4):703\u201310.","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"1245_CR20","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1080\/14779072.2020.1792293","volume":"18","author":"D Calderone","year":"2020","unstructured":"Calderone D, Capodanno D, Angiolillo DJ. An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus. Expert Rev Cardiovasc Ther. 2020;18(8):449\u201364.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"23","key":"1245_CR21","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/j.jacc.2014.03.031","volume":"63","author":"M Cattaneo","year":"2014","unstructured":"Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014;63(23):2503\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1245_CR22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/jth.12058","volume":"11","author":"MU Zafar","year":"2013","unstructured":"Zafar MU, Santos-Gallego C, Vorchheimer DA, Viles-Gonzalez JF, Elmariah S, Giannarelli C, et al. Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation. J Thromb Haemost. 2013;11(1):100\u20136.","journal-title":"J Thromb Haemost"},{"issue":"11","key":"1245_CR23","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1007\/s00392-017-1128-8","volume":"106","author":"L Schoener","year":"2017","unstructured":"Schoener L, Jellinghaus S, Richter B, Pfluecke C, Ende G, Christoph M, et al. Reversal of the platelet inhibitory effect of the P2Y(12) inhibitors clopidogrel, prasugrel, and ticagrelor in vitro: a new approach to an old issue. Clin Res Cardiol. 2017;106(11):868\u201374.","journal-title":"Clin Res Cardiol"},{"issue":"2","key":"1245_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jacbts.2017.01.007","volume":"2","author":"GO Angheloiu","year":"2017","unstructured":"Angheloiu GO, Gugiu GB, Ruse C, Pandey R, Dasari RR, Whatling C. Ticagrelor removal from human blood. JACC Basic Transl Sci. 2017;2(2):135\u201345.","journal-title":"JACC Basic Transl Sci."},{"issue":"22","key":"1245_CR25","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1182\/blood-2015-01-622928","volume":"125","author":"A Buchanan","year":"2015","unstructured":"Buchanan A, Newton P, Pehrsson S, Inghardt T, Antonsson T, Svensson P, et al. Structural and functional characterization of a specific antidote for ticagrelor. Blood. 2015;125(22):3484\u201390.","journal-title":"Blood"},{"issue":"7","key":"1245_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201202","volume":"13","author":"AS Sandinge","year":"2018","unstructured":"Sandinge AS, Janefeldt A, Pehrsson S, Nylander S. Quantification of unbound concentration of ticagrelor in plasma as a proof of mechanism biomarker of the reversal agent, MEDI2452. PLoS ONE. 2018;13(7): e0201202.","journal-title":"PLoS ONE"},{"issue":"6","key":"1245_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/psp4.12089","volume":"5","author":"J Almquist","year":"2016","unstructured":"Almquist J, Penney M, Pehrsson S, Sandinge AS, Janefeldt A, Maqbool S, et al. Unraveling the pharmacokinetic interaction of ticagrelor and MEDI2452 (ticagrelor antidote) by mathematical modeling. CPT Pharmacometrics Syst Pharmacol. 2016;5(6):313\u201323.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"1245_CR28","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1177\/0091270008315318","volume":"48","author":"JS Barrett","year":"2008","unstructured":"Barrett JS, Fossler MJ, Cadieu KD, Gastonguay MR. Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings. J Clin Pharmacol. 2008;48(5):632\u201349.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1245_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s002590050216","volume":"25","author":"TM Behr","year":"1998","unstructured":"Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 1998;25(2):201\u201312.","journal-title":"Eur J Nucl Med"},{"issue":"6","key":"1245_CR30","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1111\/jth.13680","volume":"15","author":"S Pehrsson","year":"2017","unstructured":"Pehrsson S, Johansson KJ, Janefeldt A, Sandinge AS, Maqbool S, Goodman J, et al. Hemostatic effects of the ticagrelor antidote MEDI2452 in pigs treated with ticagrelor on a background of aspirin. J Thromb Haemost. 2017;15(6):1213\u201322.","journal-title":"J Thromb Haemost"},{"issue":"19","key":"1245_CR31","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1056\/NEJMoa1901778","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Pollack CV, Weitz JI, Jennings LK, Xu S, Arnold SE, et al. Antibody-based ticagrelor reversal agent in healthy volunteers. N Engl J Med. 2019;380(19):1825\u201333.","journal-title":"N Engl J Med"},{"issue":"1","key":"1245_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/psp4.12734","volume":"11","author":"SJ Kathman","year":"2022","unstructured":"Kathman SJ, Wheeler JJ, Bhatt DL, Arnold SE, Lee JS. Population pharmacokinetic-pharmacodynamic modeling of PB2452, a monoclonal antibody fragment being developed as a ticagrelor reversal agent, in healthy volunteers. CPT Pharmacometr Syst Pharmacol. 2022;11(1):68\u201381.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"1245_CR33","unstructured":"U.S. NLM. Study to evaluate the safety, tolerability, PK and PD of PB2452 in healthy younger, older and elderly subjects. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03928353. Accessed 16 Dec 2022."},{"key":"1245_CR34","unstructured":"PhaseBio-Pharmaceuticals. PhaseBio announces completion of phase 2a clinical trial of PB2452 for the reversal of the antiplatelet activity of ticagrelor of PB2452 for the reversal of the antiplatelet activity of ticagrelor. 2019. https:\/\/investors.phasebio.com\/news-releases\/news-release-details\/phasebio-announces-completion-phase-2a-clinical-trial-pb2452\/. Accessed 13 Dec 2022."},{"key":"1245_CR35","unstructured":"PhaseBio-Pharmaceuticals. PhaseBio announces positive preliminary results from phase 2a clinical trial of PB2452 for the reversal of the antiplatelet activity of ticagrelor in older and elderly subjects. 2019. https:\/\/investors.phasebio.com\/news-releases\/news-release-details\/phasebio-announces-positive-preliminary-results-phase-2a\/. Accessed 13 Dec 2022."},{"key":"1245_CR36","unstructured":"PhaseBio-Pharmaceuticals. Corporate overview. 2021. https:\/\/investors.phasebio.com\/static-files\/0be2e15a-8c3d-4698-877d-11c9a3be7a76. Accessed 14 Dec 2022."},{"key":"1245_CR37","unstructured":"PhaseBio-Pharmaceuticals. PhaseBio announces positive results from phase 2b trial for bentracimab. 2022. https:\/\/investors.phasebio.com\/news-releases\/news-release-details\/phasebio-announces-positive-results-phase-2b-trial-bentracimab. Accessed 14 Dec 2022."},{"key":"1245_CR38","unstructured":"U.S. NLM. Phase 2B study to evaluate the efficacy of bentracimab (PB2452) in reversal of ticagrelor in subjects aged 50-80 years old. 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04122170. Accessed 14 Dec 2022."},{"key":"1245_CR39","unstructured":"Bhatt DL. Bentracimab immediately and significantly reverses the antiplatelet effects of ticagrelor in older people. ACC Annual Scientific Session, 2\u20134of April 2022, Washington DC; 2022."},{"key":"1245_CR40","doi-asserted-by":"crossref","unstructured":"Curry B, Brown R, Bhatt D, Arnold S, Lee J, Jennings L. Bentracimab demonstrates reversal of antiplatelet effects of ticagrelor: impact of hematocrit and generic versions of ticagrelor in vitro. Eur Heart J. 2022;43(Suppl_2).","DOI":"10.1093\/eurheartj\/ehac544.2720"},{"key":"1245_CR41","doi-asserted-by":"crossref","unstructured":"Bhatt DL, Pollack CV, Mazer CD, Angiolillo DJ, Steg PG, James SK, et al. Bentracimab for ticagrelor reversal in patients undergoing urgent surgery. NEJM Evid. 2022;1(3):EVIDoa2100047.","DOI":"10.1056\/EVIDoa2100047"},{"key":"1245_CR42","doi-asserted-by":"crossref","unstructured":"Investigators G. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329(10):673\u201382.","DOI":"10.1056\/NEJM199309023291001"},{"issue":"14","key":"1245_CR43","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","volume":"380","author":"SJ Connolly","year":"2019","unstructured":"Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, et al. Full study report of andexanet alfa for bleeding associated with Factor Xa inhibitors. N Engl J Med. 2019;380(14):1326\u201335.","journal-title":"N Engl J Med"},{"key":"1245_CR44","unstructured":"Bhatt DL. Effect of bentracimab on platelet inhibition and hemostasis in patients on ticagrelor with major bleeding or requiring urgent procedures. American Heart Association Scientific Sessions, 13\u201315th of November; 2021; Boston (MA)."},{"issue":"5","key":"1245_CR45","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1056\/NEJMoa1707278","volume":"377","author":"CV Pollack Jr","year":"2017","unstructured":"Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for dabigatran reversal: full cohort analysis. N Engl J Med. 2017;377(5):431\u201341.","journal-title":"N Engl J Med"},{"issue":"8","key":"1245_CR46","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1111\/jocs.15636","volume":"36","author":"A Makhdoum","year":"2021","unstructured":"Makhdoum A, Dhingra NK, Kirubaharan A, Eikelboom R, Luc J, Dagher O, et al. Ticagrelor use and practice patterns among Canadian cardiac surgeons. J Card Surg. 2021;36(8):2793\u2013801.","journal-title":"J Card Surg"},{"key":"1245_CR47","unstructured":"U.S. NLM. Study to evaluate the safety, tolerability, PK, and PD of PB2452 with and without ticagrelor pretreatment in Chinese healthy volunteers. 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05162131. Accessed 15 Dec 2022."},{"key":"1245_CR48","unstructured":"AstraZeneca. AstraZeneca announces initiation of development programme for BRILINTA\u00ae reversal agent. 2014. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2014\/astrazeneca-brilinta-development-programme-cardiovascular-13112014.html#. Accessed 15 Dec 2022."},{"key":"1245_CR49","unstructured":"PhaseBio-Pharmaceuticals. PhaseBio enters worldwide license agreement with MedImmune for a reversal agent for ticagrelor. 2017. https:\/\/investors.phasebio.com\/news-releases\/news-release-details\/phasebio-enters-worldwide-license-agreement-medimmune-reversal\/. Accessed 15 Dec 2022."},{"key":"1245_CR50","unstructured":"PhaseBio-Pharmaceuticals. PhaseBio Pharmaceuticals achieves enrollment milestones supporting interim analysis of REVERSE-IT global phase 3 trial, enabling preparation of a BLA submission for bentracimab for reversal of antiplatelet effects of ticagrelor. 2021. https:\/\/investors.phasebio.com\/news-releases\/news-release-details\/phasebio-pharmaceuticals-achieves-enrollment-milestones. Accessed 15 Dec 2022."},{"key":"1245_CR51","unstructured":"PhaseBio-Pharmaceuticals. PhaseBio announces successful pre-BLA meeting with U.S. FDA for bentracimab. 2022. https:\/\/investors.phasebio.com\/news-releases\/news-release-details\/phasebio-announces-successful-pre-bla-meeting-us-fda-bentracimab. Accessed 15 Dec 2022."},{"key":"1245_CR52","unstructured":"PhaseBio-Pharmaceuticals. PhaseBio reports first quarter 2020 financial results and recent business highlights. 2022. https:\/\/investors.phasebio.com\/news-releases\/news-release-details\/phasebio-reports-first-quarter-2020-financial-results-and-recent\/. Accessed 15 Dec 2022."},{"key":"1245_CR53","unstructured":"PhaseBio-Pharmaceuticals. PhaseBio Pharmaceuticals and SFJ Pharmaceuticals\u00ae announce approval of IND application in China for bentracimab. 2021. https:\/\/investors.phasebio.com\/news-releases\/news-release-details\/phasebio-pharmaceuticals-and-sfj-pharmaceuticalsr-announce. Accessed 16 Dec 2022."},{"key":"1245_CR54","unstructured":"PhaseBio-Pharmaceuticals. PhaseBio announces dosing of first patient in European Union as part of REVERSE-IT global phase 3 trial of bentracimab for reversal of antiplatelet effects of ticagrelor. 2021. https:\/\/investors.phasebio.com\/news-releases\/news-release-details\/phasebio-announces-dosing-first-patient-european-union-part. Accessed 16 Dec 2022."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01245-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-023-01245-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01245-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T13:18:47Z","timestamp":1683897527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-023-01245-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1245"],"URL":"https:\/\/doi.org\/10.1007\/s40262-023-01245-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]},"assertion":[{"value":"20 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Francesco Franchi declares that he has received payment as an individual for consulting fees or honoraria from AstraZeneca, Bayer, and Sanofi; and institutional payments for grants from PLx Pharma and The Scott R. MacKenzie Foundation. Charles V. Pollack Jr discloses the following relationships pertinent to this work: consulting fees or honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, PhaseBio, Provepharm, Milestone, and eXIthera; and research support from AstraZeneca, Provepharm, eXIthera, Janssen Pharma, CSL\/Behring, DaiichiSankyo, and Portola. Deepak L. Bhatt discloses the following relationships: Advisory Board: Angiowave, Bayer, Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, and Stasys; Board of Directors: Angiowave (stock options), Boston VA Research Institute, Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock), Society of Cardiovascular Patient Care, TobeSoft; Chair: Inaugural Chair, American Heart Association Quality Oversight Committee; Consultant: Broadview Ventures; Data Monitoring Committees: Acesion Pharma, Assistance Publique-H\u00f4pitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial); honoraria: American College of Cardiology (Senior Associate Editor, <i>Clinical Trials and News<\/i>, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi\/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, <i>Harvard Heart Letter<\/i>), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, <i>Journal of Invasive Cardiology<\/i>), <i>Journal of the American College of Cardiology<\/i> (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence\/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, <i>Cardiology Today\u2019s Intervention<\/i>), Society of Cardiovascular Patient Care (Secretary\/Treasurer), WebMD (CME steering committees), Wiley (steering committee); other: <i>Clinical Cardiology<\/i> (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women\u2019s Hospital who assigned to Lexicon; neither Francesco Franchi nor Brigham and Women\u2019s Hospital receives any income from this patent); research funding: Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, 89Bio; Royalties: Elsevier (Editor, <i>Braunwald\u2019s Heart Disease<\/i>); site co-investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions; trustee: American College of Cardiology; unfunded research: FlowCo and Takeda. Dominick J. Angiolillo has received consulting fees or honoraria from Abbott, Amgen, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, Novartis, PhaseBio, PLx Pharma, Pfizer, Sanofi, and Vectura; he also declares that his institution has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, and the Scott R. MacKenzie Foundation. Luis Ortega-Paz, Salvatore Giordano, and Fabiana Rollini have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data sharing does not apply to this article as no datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"LO-P, SG, and DJA: conceptualization, methodology, project administration, visualization, writing, reviewing and editing. FF FR, CVP, DLB: reviewing and editing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}